Do analysts recommend BDRX or ONCO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, BDRX or ONCO?

Biodexa Pharmaceuticals has higher earnings, but lower revenue than Onconetix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals $470K 6.26 -$8.42M N/A N/A Onconetix $810K 1.27 -$14.03M $11.40 0.08

Do analysts recommend ONCO or CELZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media favor ONCO or CELZ?

In the previous week, Creative Medical Technology had 8 more articles in the media than Onconetix. MarketBeat recorded 10 mentions for Creative Medical Technology and 2 mentions for Onconetix. Creative Medical Technology's average media sentiment score of 0.55 beat Onconetix's score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Onconetix 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Creative Medical Technology 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PPCB or ONCO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to PPCB or ONCO?

In the previous week, Propanc Biopharma had 1 more articles in the media than Onconetix. MarketBeat recorded 3 mentions for Propanc Biopharma and 2 mentions for Onconetix. Propanc Biopharma's average media sentiment score of 0.47 beat Onconetix's score of 0.00 indicating that Propanc Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Propanc Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Onconetix 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend GOVX or ONCO?

GeoVax Labs presently has a consensus target price of $150.00, indicating a potential upside of 20,698.67%. Given GeoVax Labs' stronger consensus rating and higher possible upside, research analysts clearly believe GeoVax Labs is more favorable than Onconetix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GOVX or ONCO more profitable?

GeoVax Labs has a net margin of 0.00% compared to Onconetix's net margin of -1,316.28%. Onconetix's return on equity of -101.08% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -743.64% -394.74% Onconetix -1,316.28% -101.08% -47.34%

Does the media favor GOVX or ONCO?

In the previous week, GeoVax Labs had 2 more articles in the media than Onconetix. MarketBeat recorded 4 mentions for GeoVax Labs and 2 mentions for Onconetix. GeoVax Labs' average media sentiment score of 0.88 beat Onconetix's score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeoVax Labs 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Onconetix 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate DCOY or ONCO?

Decoy Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 638.92%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Decoy Therapeutics is more favorable than Onconetix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer DCOY or ONCO?

In the previous week, Onconetix had 1 more articles in the media than Decoy Therapeutics. MarketBeat recorded 2 mentions for Onconetix and 1 mentions for Decoy Therapeutics. Decoy Therapeutics' average media sentiment score of 0.00 equaled Onconetix'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Decoy Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Onconetix 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Onconetix (ONCO) Competitors

$0.90 -0.10 (-10.08%)

Closing price 08/6/2026 04:00 PM Eastern

Extended Trading

$0.91 +0.00 (+0.48%)

As of 07:27 AM Eastern

Compare

ONCO vs. BDRX, CELZ, PPCB, GOVX, and DCOY

Should you buy Onconetix stock or one of its competitors? MarketBeat compares Onconetix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Onconetix include Biodexa Pharmaceuticals (BDRX), Creative Medical Technology (CELZ), Propanc Biopharma (PPCB), GeoVax Labs (GOVX), and Decoy Therapeutics (DCOY). These companies are all part of the "biotechnology" industry.

How does Onconetix compare to Biodexa Pharmaceuticals?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and Onconetix (NASDAQ:ONCO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 23.9% of Onconetix shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Onconetix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Biodexa Pharmaceuticals has a net margin of 0.00% compared to Onconetix's net margin of -1,316.28%. Biodexa Pharmaceuticals' return on equity of 0.00% beat Onconetix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
Onconetix	-1,316.28%	-101.08%	-47.34%

Biodexa Pharmaceuticals has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, Onconetix has a beta of 2.69, meaning that its stock price is 169% more volatile than the broader market.

In the previous week, Onconetix had 2 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 2 mentions for Onconetix and 0 mentions for Biodexa Pharmaceuticals. Biodexa Pharmaceuticals' average media sentiment score of 0.00 equaled Onconetix'saverage media sentiment score.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Neutral
Onconetix	Neutral

Biodexa Pharmaceuticals has higher earnings, but lower revenue than Onconetix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	$470K	6.26	-$8.42M	N/A	N/A
Onconetix	$810K	1.27	-$14.03M	$11.40	0.08

Summary

Biodexa Pharmaceuticals beats Onconetix on 6 of the 10 factors compared between the two stocks.

How does Onconetix compare to Creative Medical Technology?

Onconetix (NASDAQ:ONCO) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Creative Medical Technology has lower revenue, but higher earnings than Onconetix. Creative Medical Technology is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$810K	1.27	-$14.03M	$11.40	0.08
Creative Medical Technology	$10K	545.10	-$5.99M	-$2.14	N/A

Creative Medical Technology has a net margin of 0.00% compared to Onconetix's net margin of -1,316.28%. Creative Medical Technology's return on equity of -88.38% beat Onconetix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,316.28%	-101.08%	-47.34%
Creative Medical Technology	N/A	-88.38%	-84.71%

Onconetix has a beta of 2.69, indicating that its stock price is 169% more volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

23.9% of Onconetix shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 0.3% of Onconetix shares are owned by company insiders. Comparatively, 1.0% of Creative Medical Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Creative Medical Technology had 8 more articles in the media than Onconetix. MarketBeat recorded 10 mentions for Creative Medical Technology and 2 mentions for Onconetix. Creative Medical Technology's average media sentiment score of 0.55 beat Onconetix's score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Onconetix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Creative Medical Technology	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Creative Medical Technology beats Onconetix on 8 of the 14 factors compared between the two stocks.

How does Onconetix compare to Propanc Biopharma?

Propanc Biopharma (NASDAQ:PPCB) and Onconetix (NASDAQ:ONCO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Onconetix has higher revenue and earnings than Propanc Biopharma. Propanc Biopharma is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A
Onconetix	$810K	1.27	-$14.03M	$11.40	0.08

In the previous week, Propanc Biopharma had 1 more articles in the media than Onconetix. MarketBeat recorded 3 mentions for Propanc Biopharma and 2 mentions for Onconetix. Propanc Biopharma's average media sentiment score of 0.47 beat Onconetix's score of 0.00 indicating that Propanc Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Propanc Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Onconetix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

23.9% of Onconetix shares are held by institutional investors. 28.5% of Propanc Biopharma shares are held by company insiders. Comparatively, 0.3% of Onconetix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Propanc Biopharma has a beta of 3.52, meaning that its stock price is 252% more volatile than the broader market. Comparatively, Onconetix has a beta of 2.69, meaning that its stock price is 169% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Propanc Biopharma has a net margin of 0.00% compared to Onconetix's net margin of -1,316.28%. Onconetix's return on equity of -101.08% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
Onconetix	-1,316.28%	-101.08%	-47.34%

Summary

Onconetix beats Propanc Biopharma on 7 of the 12 factors compared between the two stocks.

How does Onconetix compare to GeoVax Labs?

GeoVax Labs (NASDAQ:GOVX) and Onconetix (NASDAQ:ONCO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

In the previous week, GeoVax Labs had 2 more articles in the media than Onconetix. MarketBeat recorded 4 mentions for GeoVax Labs and 2 mentions for Onconetix. GeoVax Labs' average media sentiment score of 0.88 beat Onconetix's score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeoVax Labs	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Onconetix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Onconetix has lower revenue, but higher earnings than GeoVax Labs. GeoVax Labs is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	1.01	-$21.47M	-$11.34	N/A
Onconetix	$810K	1.27	-$14.03M	$11.40	0.08

GeoVax Labs presently has a consensus target price of $150.00, indicating a potential upside of 20,698.67%. Given GeoVax Labs' stronger consensus rating and higher possible upside, research analysts clearly believe GeoVax Labs is more favorable than Onconetix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 23.9% of Onconetix shares are held by institutional investors. 0.7% of GeoVax Labs shares are held by company insiders. Comparatively, 0.3% of Onconetix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

GeoVax Labs has a beta of 3.73, indicating that its stock price is 273% more volatile than the broader market. Comparatively, Onconetix has a beta of 2.69, indicating that its stock price is 169% more volatile than the broader market.

GeoVax Labs has a net margin of 0.00% compared to Onconetix's net margin of -1,316.28%. Onconetix's return on equity of -101.08% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
Onconetix	-1,316.28%	-101.08%	-47.34%

Summary

GeoVax Labs beats Onconetix on 8 of the 15 factors compared between the two stocks.

How does Onconetix compare to Decoy Therapeutics?

Decoy Therapeutics (NASDAQ:DCOY) and Onconetix (NASDAQ:ONCO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Decoy Therapeutics has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market. Comparatively, Onconetix has a beta of 2.69, suggesting that its stock price is 169% more volatile than the broader market.

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 1.7% of Decoy Therapeutics shares are owned by insiders. Comparatively, 0.3% of Onconetix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Decoy Therapeutics has higher earnings, but lower revenue than Onconetix. Decoy Therapeutics is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A
Onconetix	$810K	1.27	-$14.03M	$11.40	0.08

Decoy Therapeutics has a net margin of 0.00% compared to Onconetix's net margin of -1,316.28%. Onconetix's return on equity of -101.08% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-395.42%	-193.30%
Onconetix	-1,316.28%	-101.08%	-47.34%

Decoy Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 638.92%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Decoy Therapeutics is more favorable than Onconetix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Onconetix had 1 more articles in the media than Decoy Therapeutics. MarketBeat recorded 2 mentions for Onconetix and 1 mentions for Decoy Therapeutics. Decoy Therapeutics' average media sentiment score of 0.00 equaled Onconetix'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Decoy Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Onconetix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Onconetix beats Decoy Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Onconetix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONCO vs. The Competition

Export

Metric	Onconetix	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.15M	$3.61B	$6.95B	$12.87B
Dividend Yield	N/A	3.76%	2.59%	9.93%
P/E Ratio	0.08	8.36	271.22	25.30
Price / Sales	1.27	1,279.23	657.29	106.23
Price / Cash	N/A	101.37	71.89	50.37
Price / Book	0.00	17.66	13.03	6.13
Net Income	-$14.03M	-$13.22M	$3.46B	$342.95M
7 Day Performance	9.31%	4.42%	3.40%	3.19%
1 Month Performance	-15.54%	-4.91%	-2.68%	-1.98%
1 Year Performance	-99.32%	56.59%	76.00%	21.11%

Onconetix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONCO Onconetix	0.6001 of 5 stars	$0.90 -10.1%	N/A	-99.4%	$1.15M	$810K	0.08	12	News Coverage Gap Down
BDRX Biodexa Pharmaceuticals	0.7475 of 5 stars	$1.55 +4.0%	N/A	-95.7%	$3.26M	$470K	N/A	20	Positive News
CELZ Creative Medical Technology	1.415 of 5 stars	$0.66 +0.4%	N/A	-67.2%	$3.13M	$3K	N/A	5	Trending News Upcoming Earnings Gap Up
PPCB Propanc Biopharma	0.623 of 5 stars	$1.20 +17.2%	N/A	-99.1%	$2.75M	N/A	N/A	1	News Coverage Gap Up
GOVX GeoVax Labs	2.4089 of 5 stars	$0.76 -0.5%	$150.00 +19,688.9%	-95.6%	$2.63M	$2.49M	N/A	10	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONCO) was last updated on 8/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Onconetix (ONCO) Competitors

ONCO vs. BDRX, CELZ, PPCB, GOVX, and DCOY

How does Onconetix compare to Biodexa Pharmaceuticals?

Summary

How does Onconetix compare to Creative Medical Technology?

Summary

How does Onconetix compare to Propanc Biopharma?

Summary

How does Onconetix compare to GeoVax Labs?

Summary

How does Onconetix compare to Decoy Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCO vs. The Competition

Onconetix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Onconetix (ONCO) Competitors

ONCO vs. BDRX, CELZ, PPCB, GOVX, and DCOY

How does Onconetix compare to Biodexa Pharmaceuticals?

Do analysts recommend BDRX or ONCO?

Do insiders & institutionals hold more shares of BDRX or ONCO?

Is BDRX or ONCO more profitable?

Which has more risk & volatility, BDRX or ONCO?

Does the media refer more to BDRX or ONCO?

Which has better valuation & earnings, BDRX or ONCO?

Summary

How does Onconetix compare to Creative Medical Technology?

Which has higher earnings & valuation, ONCO or CELZ?

Is ONCO or CELZ more profitable?

Which has more risk and volatility, ONCO or CELZ?

Do analysts recommend ONCO or CELZ?

Do insiders & institutionals believe in ONCO or CELZ?

Does the media favor ONCO or CELZ?

Summary

How does Onconetix compare to Propanc Biopharma?

Which has better valuation and earnings, PPCB or ONCO?

Does the media refer more to PPCB or ONCO?

Do insiders and institutionals believe in PPCB or ONCO?

Which has more volatility & risk, PPCB or ONCO?

Do analysts rate PPCB or ONCO?

Is PPCB or ONCO more profitable?

Summary

How does Onconetix compare to GeoVax Labs?

Does the media favor GOVX or ONCO?

Which has better valuation and earnings, GOVX or ONCO?

Do analysts recommend GOVX or ONCO?

Do institutionals and insiders believe in GOVX or ONCO?

Which has more risk and volatility, GOVX or ONCO?

Is GOVX or ONCO more profitable?

Summary

How does Onconetix compare to Decoy Therapeutics?

Which has more risk & volatility, DCOY or ONCO?

Do institutionals and insiders have more ownership in DCOY or ONCO?

Which has preferable earnings and valuation, DCOY or ONCO?

Is DCOY or ONCO more profitable?

Do analysts rate DCOY or ONCO?

Does the media prefer DCOY or ONCO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCO vs. The Competition

Onconetix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools